Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George F Tidmarsh

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Critical Care Clinics|February 21, 2019
Therapeutic Opportunities for Hepcidin in Acute Care MedicineLakhmir S Chawla, Blaire Beers-Mulroy, George F Tidmarsh
Disease Models & Mechanisms|April 26, 2013
Bridging the gap between basic and applied biology: towards preclinical translationRoss L Cagan, Monica J Justice, George F Tidmarsh
Critical Care (London, England)|April 18, 2019
Broad spectrum vasopressors: a new approach to the initial management of septic shock?Lakhmir S Chawla, Marlies Ostermann, Lui Forni, et al.
Critical Care Explorations|March 14, 2020
Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two PatientsDwight M Bailey, Ranjit S Chima, George F Tidmarsh, et al.
Neoplasia (New York, N.Y.)|September 6, 2007
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivoW Steve Ammons, Jin-Wei Wang, Zhijian Yang, et al.
Journal of Drug Assessment|August 19, 2016
Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysisJeffery D Kent, Robert J Holt, Donald Jung, et al.
Cancer Research|January 20, 2004
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoGregory Maschek, Niramol Savaraj, Waldemar Priebe, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|February 21, 2017
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trialLakhmir S Chawla, James A Russell, Sean M Bagshaw, et al.
Cancer Chemotherapy and Pharmacology|July 31, 2007
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinomaE Gabriela Chiorean, Tomislav Dragovich, John Hamm, et al.
Annals of Intensive Care|June 5, 2019
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trialKealy R Ham, David W Boldt, Michael T McCurdy, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Critical Care Clinics|February 21, 2019
Therapeutic Opportunities for Hepcidin in Acute Care MedicineLakhmir S Chawla, Blaire Beers-Mulroy, George F Tidmarsh
Disease Models & Mechanisms|April 26, 2013
Bridging the gap between basic and applied biology: towards preclinical translationRoss L Cagan, Monica J Justice, George F Tidmarsh
Critical Care (London, England)|April 18, 2019
Broad spectrum vasopressors: a new approach to the initial management of septic shock?Lakhmir S Chawla, Marlies Ostermann, Lui Forni, et al.
Critical Care Explorations|March 14, 2020
Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two PatientsDwight M Bailey, Ranjit S Chima, George F Tidmarsh, et al.
Neoplasia (New York, N.Y.)|September 6, 2007
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivoW Steve Ammons, Jin-Wei Wang, Zhijian Yang, et al.
Journal of Drug Assessment|August 19, 2016
Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysisJeffery D Kent, Robert J Holt, Donald Jung, et al.
Cancer Research|January 20, 2004
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoGregory Maschek, Niramol Savaraj, Waldemar Priebe, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|February 21, 2017
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trialLakhmir S Chawla, James A Russell, Sean M Bagshaw, et al.
Cancer Chemotherapy and Pharmacology|July 31, 2007
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinomaE Gabriela Chiorean, Tomislav Dragovich, John Hamm, et al.
Annals of Intensive Care|June 5, 2019
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trialKealy R Ham, David W Boldt, Michael T McCurdy, et al.
Pageof 2